See the DrugPatentWatch profile for lacosamide

Based on the information available, there is no specific guidance on the safety of lacosamide for pregnant women. The FDA has not classified lacosamide regarding its use in pregnancy, which means there is not enough information to determine whether it poses a risk to the fetus [1]. Therefore, pregnant women should only use this medication in consultation with their healthcare provider, who can weigh the potential benefits and risks.

Lacosamide is a prescription medication used to treat partial-onset seizures in adults and children one month of age and older [2]. It is available under the brand name Vimpat and as a generic drug [2].

Pregnant women should inform their healthcare provider about all medications they are taking, as some drugs can harm the developing fetus [1]. Healthcare providers should consider the potential benefits and risks of lacosamide use during pregnancy and discuss them with the patient [1].

It is essential to note that drug manufacturers are required to report any adverse events related to their products to the FDA [1]. However, the FDA does not require drug manufacturers to conduct studies on the safety of their products during pregnancy [1].

In summary, there is no specific guidance on the safety of lacosamide for pregnant women. Pregnant women should only use this medication in consultation with their healthcare provider.

Sources:
[1] FDA. (2021). Medication and Pregnancy: What You Need to Know. <https://www.fda.gov/consumers/free-publications-women/medication-and-pregnancy-what-you-need-know>.
[2] DrugPatentWatch. (n.d.). Lacosamide. <https://www.drugpatentwatch.com/drugs/lacosamide>.